Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary reveals strong financial performance with significant improvements in gross profit and reduced cash flow burn. The strategic collaboration with Pfizer and raised revenue guidance are positive indicators. The Q&A section highlights growth in key products and strong market positioning, despite some uncertainties around Shield V2 data and payer coverage. The market cap suggests moderate volatility, leading to a positive prediction for the stock price movement over the next two weeks.
Q2 revenue $232 million, grew 31% year-over-year. Strong performance across oncology, screening, and biopharma and data businesses.
Oncology revenue $159 million, increased 22% year-over-year. Driven by 30% increase in oncology volumes to approximately 64,000 tests, with majority growth from Guardant360 Liquid and strong contribution from Reveal.
Guardant360 Liquid volume growth Over 20% year-over-year, accelerated for the fourth consecutive quarter. Driven by new app introductions powered by Smart Liquid Biopsy.
Guardant360 Tissue ASP Approximately $2,000 in Q2, achieving 2028 target 3 years early. Driven by Medicare pricing increase, progress with commercial payers, and RNA feature reimbursement.
Reveal ASP $600 to $700, following Medicare CRC surveillance coverage earlier in the year.
Biopharma and data revenue $56 million, grew 28% year-over-year. Record quarter with all-time highs in volume and revenue. Driven by Guardant Infinity and new companion diagnostic partnerships.
Shield testing revenue $15 million, driven by approximately 16,000 tests. High adherence rates over 90% and strong depth of ordering per physician.
Shield ASP Over $900 in Q2, increased from $600 in Q1. Driven by Medicare rate increase and high mix of reimbursable test volume.
Shield non-GAAP cost per test Less than $500, reduced from prior quarters. Driven by increased volume and operational efficiency.
Non-GAAP gross margin 66%, improved from 60% in Q2 2024. Driven by improved oncology ASPs and turnaround in gross margins for Reveal and Shield.
Non-GAAP gross profit $153.8 million, increased 44% year-over-year. Improvement due to higher ASPs and gross margin improvements in Reveal and Shield.
Adjusted EBITDA loss $51.9 million, improved by $10 million compared to Q2 2024. Reflects focus on cash management and reduced burn.
Free cash flow burn $65.9 million, reduced from $99.1 million in Q2 2024. Reflects improved cash management.
Cash, cash equivalents, and restricted cash $735 million at the end of the quarter.
Guardant360 Liquid: Achieved over 20% year-over-year growth in Q2, driven by new Smart Liquid Biopsy applications.
Guardant360 Tissue: Major upgrade in April 2025, achieving $2,000 ASP in Q2, three years ahead of the 2028 target.
Reveal: Submitted breast cancer data for Medicare reimbursement and published immuno-oncology therapy monitoring data.
Shield CRC: Generated $15 million in Q2 revenue with 16,000 tests, achieving over 90% adherence rates.
International Expansion: Guardant360 Liquid and Tissue adoption increased internationally, driven by expanded genomic and epigenomic capabilities.
NCCN Guidelines: Shield CRC included in NCCN guidelines, paving the way for improved commercial coverage and patient access.
Revenue Growth: Q2 revenue grew 31% year-over-year to $232 million, with oncology contributing $159 million.
Gross Margin Improvement: Non-GAAP gross margin improved to 66% in Q2, driven by higher ASPs and cost reductions in Shield and Reveal.
Cash Flow Management: Free cash flow burn reduced to $65.9 million in Q2, with $735 million in cash reserves.
Shield Multi-Cancer Detection (MCD): Received FDA breakthrough device designation and commenced inclusion in the NCI Vanguard study.
Commercial Infrastructure: Accelerating Shield's commercial build-out with plans to surpass 250 sales reps by year-end 2025.
Regulatory hurdles: The company faces challenges in obtaining Medicare reimbursement for new products, as evidenced by the ongoing submission process for Reveal breast cancer data to MolDx for Medicare reimbursement.
Economic uncertainties: The company is heavily investing in sales and marketing, particularly for Shield, which could strain financial resources if revenue growth does not meet expectations. Additionally, the company is operating at a loss, with a free cash flow burn of $65.9 million in Q2 2025.
Competitive pressures: The company is expanding its Shield product line and increasing its sales force to 250 reps by year-end, indicating a highly competitive market environment that requires aggressive investment to maintain market share.
Supply chain and operational risks: The company is scaling its Shield business rapidly, which could lead to operational inefficiencies or supply chain disruptions if not managed effectively.
Strategic execution risks: The company’s ambitious growth targets, including achieving cash flow breakeven by 2028 and scaling Shield volumes significantly, depend on flawless execution, which may be challenging given the complexity of its operations and market dynamics.
Revenue Guidance: Full year 2025 revenue guidance increased to $915 million to $925 million, representing growth of approximately 24% to 25% compared to 2024.
Oncology Revenue: Expected to grow approximately 20% year-over-year in 2025, driven by stronger-than-expected Guardant360 Liquid and Reveal volumes.
Oncology Volume: Total oncology volume projected to grow greater than 27% in 2025.
Biopharma and Data Business: Expected mid-teens revenue growth in 2025, an increase from prior guidance of low double-digit growth.
Shield Revenue: Full year 2025 Shield revenue guidance raised to $55 million to $60 million, driven by higher volume expectations of 68,000 to 73,000 tests.
Shield ASP: Anticipated ASP of approximately $800 for the second half of 2025, slightly lower than Q2 ASP due to potential changes in payer mix.
Non-GAAP Gross Margin: Full year 2025 non-GAAP gross margin guidance raised to 63% to 64%, up from the previous range of 62% to 63%.
Non-GAAP Operating Expenses: Expected to be in the range of $840 million to $850 million for 2025, representing an 11% to 12% increase compared to 2024.
Free Cash Flow Burn: Full year 2025 free cash flow burn expected to be in the range of $225 million to $235 million, an improvement compared to $275 million in 2024.
Cash Flow Breakeven: Excluding screening, the company expects to reach free cash flow breakeven in Q4 2025.
The selected topic was not discussed during the call.
The earnings call summary and Q&A indicate strong revenue growth and optimistic guidance, particularly in oncology and Shield revenues. Despite some uncertainties in FDA timelines and 2026 growth, the positive reception of MCD and Guardant360's growth drivers, along with raised revenue guidance and improved margins, suggest a positive outlook. The market cap indicates a moderate reaction, leading to a 'Positive' sentiment prediction for the stock price over the next two weeks.
The earnings call summary reveals strong financial performance with significant improvements in gross profit and reduced cash flow burn. The strategic collaboration with Pfizer and raised revenue guidance are positive indicators. The Q&A section highlights growth in key products and strong market positioning, despite some uncertainties around Shield V2 data and payer coverage. The market cap suggests moderate volatility, leading to a positive prediction for the stock price movement over the next two weeks.
Despite positive revenue growth and improved gross margins, the company's increasing cash burn and lack of a share buyback program raise concerns. The Q&A section shows optimism about product development and market expansion, but management's unclear responses about market share and trial timelines add uncertainty. Given the company's market cap, the stock price is likely to remain stable, resulting in a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
